Deciphering the role of PLCD3 in lung cancer: A gateway to glycolytic reprogramming via PKC-Rap1 activation
Liang Zhang,
Mingjiang Li,
Xiaoping Li,
Ting Xiao,
Honggang Zhou,
Weidong Zhang,
Ping Wang
Affiliations
Liang Zhang
Tianjin Medical University Cancer Institute & Hospital, Tianjin, PR China; Department of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, PR China; Corresponding author. Department of Thoracic Surgery, Tianjin First Central Hospital, 300192, Tianjin, PR China.
Mingjiang Li
Department of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, PR China
Xiaoping Li
Department of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, PR China
Ting Xiao
College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, PR China
Honggang Zhou
College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, PR China
Weidong Zhang
Department of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, PR China; Corresponding author. Department of Thoracic Surgery, Tianjin First Central Hospital, 300192, Tianjin, PR China.
Ping Wang
Tianjin Medical University Cancer Institute & Hospital, Tianjin, PR China; Corresponding author. Tianjin Medical University Cancer Institute & Hospital, 300060, Tianjin, PR China.
PLCD3 belongs to the phospholipase C delta group and is involved in numerous biological functions, including cell growth, programmed cell death, and specialization. However, the role of PLCD3 in lung cancer still needs further investigation. This research aimed to investigate if PLCD3 influences glycolytic reprogramming and lung cancer development through the PKC-dependent Rap1 signaling pathway. This study found that PLCD3 was increased in lung cancer tissues. PLCD3 promotes the proliferation and invasion of lung cancer cells by activating the PKC-dependent Rap1 pathway. The detailed process involves PLCD3 triggering PKC, which subsequently stimulates the Rap1 pathway, leading to glycolytic reprogramming that supplies adequate energy and metabolic substrates necessary for the growth and spread of lung cancer cells. Moreover, PLCD3 can also promote the metastasis and invasion of lung cancer cells by activating the Rap1 pathway. This study reveals the mechanism of PLCD3 in lung cancer and provides new ideas for the treatment of lung cancer. Inhibiting PLCD3, PKC, and the Rap1 pathway may be an effective strategy for treating lung cancer.
